Tufts University School of Medicine
Division of Tufts University
Latest From Tufts University School of Medicine
Flagship Ventures has recruited former Merck Chief Medical Officer Michael Rosenblatt as its CMO to mentor biopharma startups in the venture firm's portfolio – a hire that appears to be the first of its kind.
A field littered with failures sees few companies brave enough to try again. A big market awaits medtech start-ups that find a successful way to end the need for autografts and allografts for soft-tissue repair.
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Tech Transfers column provides a monthly update on technology transfer deals, reporting licensing agreements between companies and universities or other research institutions within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors.
Overactive membrane attack complex (MAC) in retinal host tissue may underlie the development of the drusen fatty deposits characteristic of dry age-related macular degeneration and the leaky vasculature in the wet form of AMD, which can eventually blot out central vision. Hemera Biosciences Inc. is developing a single-injection gene therapy with the potential to rebalance the complement system in the retina and induce lifetime protection against disease progression for both wet and dry forms of AMD.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.